Titan Biotech (BOM:524717) Beta: -2.0181 (As of Jun. 29, 2026)


BOM:524717 Titan Biotech Ltd BOM:524717
50 GF Score
Price ₹397.90
GF Value ₹143.96
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Titan Biotech Beta?

Titan Biotech BOM:524717 +0.21% 50 Beta is -2.0181 as of Jun. 29, 2026. GuruFocus rates BOM:524717 with a GF Score™ of 50/100 and a GF Value™ of ₹143.96 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-29), Titan Biotech's Beta is -2.0181.


Titan Biotech  (BOM:524717) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Titan Biotech Beta Related Terms


Titan Biotech Beta Historical Data

* Premium members only.

The historical data trend for Titan Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Biotech Beta Chart

Titan Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 -0.13 -0.36 0.48 -2.25

Titan Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.32 -0.14 -0.18 -2.25

BOM:524717 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Titan Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Biotech Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Biotech's Beta distribution charts can be found below:

* The bar in red indicates where Titan Biotech's Beta falls into.


BOM:524717
50GF Score
Titan Biotech Ltd BOM:524717
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -2.0181 mean?
Titan Biotech (BOM:524717) has a Beta of -2.0181 as of Jun. 29, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Titan Biotech and its competitors.
Is Titan Biotech's Beta too high?
Titan Biotech's current Beta is -2.0181. Overall, Titan Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Beta compare to VRTX and REGN?
Titan Biotech's Beta of -2.0181 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Titan Biotech and its competitors. Titan Biotech's current Beta is -2.0181. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹143.96, compared to a current price of ₹397.90 — trading 176.4% above its estimated fair value. The current Beta is -2.0181. Titan Biotech's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Beta is -2.0181 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Titan Biotech (BOM:524717) Overvalued in 2026?

Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued. The current stock price of ₹397.90 is trading 176.4% above its estimated GF Value™ of ₹143.96. GuruFocus considers Titan Biotech to be Significantly Overvalued.

Key valuation signals for BOM:524717:

  • Beta: -2.0181
  • GF Value™: ₹143.96 vs. price of ₹397.90 (176.4% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Titan Biotech Business Description

Address Netaji Subhash Place, 903-909, 9th Floor, Bigjos Tower, New Delhi, IND, 110034
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
50GF Score

Get the complete analysis for BOM:524717

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹397.90
Price
₹143.96
GF Value